What is claimed:

1. A use of erdafitinib in the manufacture of a medicament for the treatment of urothelial carcinoma in a patient, wherein the medicament is to be co-administered with a P-glycoprotein (P-gp) substrate and administration of erdafitinib is to be separated by at least 6 hours before or after administration of the P-gp substrate, in particular wherein the P-gp substrate has a narrow therapeutic index.

2. A use of erdafitinib in the manufacture of a medicament for the treatment of urothelial carcinoma in a patient, wherein the medicament is to be co-administered with a moderate CYP2C9 or CYP3A4 inducer.

3. The use according to claim 2, wherein the moderate CYP2C9 or CYP3A4 inducer is to be co-administered at the start of erdafitinib treatment.

4. The use of any one of claims 1 to 3, wherein the urothelial carcinoma is locally advanced or metastatic.

5. The use of any one of claims 1 to 4, wherein the urothelial carcinoma is susceptible to an FGFR2 genetic alteration or an FGFR3 genetic alteration.

6. The use of claim 5, wherein the FGFR2 or FGFR3 genetic alteration is an FGFR3 gene mutation or an FGFR2 or FGFR3 gene fusion.

7. The use of claim 6, wherein the FGFR3 gene mutation is R248C, S249C, G370C, Y373C, or any combination thereof.

8. The use of claim 6, wherein the FGFR2 or FGFR3 gene fusion is FGFR3-TACC3, FGFR3-BAIAP2L1, FGFR2-BICC1, FGFR2-CASP7, or any combination thereof.

9. The use of any of one claims 1 to 8, wherein a biological sample from the patient is to be evaluated for the presence of one or more FGFR2 or FGFR3 genetic alterations prior to administration of erdafitinib.

10. The use of claim 9, wherein the biological sample is blood, lymph fluid, bone marrow, a solid tumor sample, or any combination thereof.

11. The use of any one of claims 1 to 10, wherein the patient is to receive at least one prior therapy for the treatment of urothelial carcinoma.

12. The use of claim 11, wherein the at least one prior therapy for the treatment of urothelial carcinoma is platinum-containing chemotherapy.

13. The use of claim 11, wherein the urothelial carcinoma progressed during or following at least one line of the platinum-containing chemotherapy.

14. The use of claim 12, wherein the platinum-containing chemotherapy is neoadjuvant platinum-containing chemotherapy or adjuvant platinum-containing chemotherapy.

15. The use of claim 14, wherein the urothelial carcinoma progressed during or within 12 months following at least one line of the neoadjuvant platinum-containing chemotherapy or adjuvant platinum-containing chemotherapy.

16. The use of any one of claims 1 to 15, wherein erdafitinib is to be administered daily.

17. The use of any one of claims 1 to 16, wherein erdafitinib is to be administered orally.

18. The use of claim 16 or 17, wherein erdafitinib is to be administered orally on a continuous daily dosing schedule.

19. The use of claim 18, wherein erdafitinib is to be administered orally at a dose of about 8 mg once daily.

20. The use of claim 19, wherein the dose of erdafitinib is to be increased from 8 mg once daily to 9 mg once daily at 14 to 21 days after initiating treatment if:
(a) the patient exhibits a serum phosphate (PO_4) level that is less than about 5.5 mg/dL at 14-21 days after initiating treatment; and
(b) administration of erdafitinib at 8 mg once daily resulted in no ocular disorder; or
(c) administration of erdafitinib at 8 mg once daily resulted in no Grade 2 or greater adverse reaction.

21. The use of any one of claims 1 to 20, wherein erdafitinib is present in a solid dosage form.

22. The use of claim 21, wherein the solid dosage form is a tablet.